483
Zhejiang Kangle Pharmaceutical Co., Ltd (Binhai Plant)FDA 483 - Zhejiang Kangle Pharmaceutical Co., Ltd (Binhai Plant) - March 22, 2019
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
Record Details
An FDA inspection of Zhejiang Kangle Pharmaceutical Co Ltd, a finished dose intermediate manufacturer in Wenzhou, Zhejiang, PRC, revealed significant deficiencies. Observations included failures in securing and controlling cleaning documents, inadequate cleaning procedures and documentation, and a lack of proper training for production employees on deviation reporting. These issues suggest a concerning lack of adherence to established quality control protocols.
- Inspection Date
- March 22, 2019
- Product Type
- Drugs
Open in Dashboard
ID · 39f6750c-499f-4041-a4d2-0acaa910a734